{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:08:49Z","timestamp":1791407329187,"version":"4.3.3"},"reference-count":40,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"name":"Foundation of China","award":["82202802"],"award-info":[{"award-number":["82202802"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have cardiovascular benefits, but whether this is via metabolic improvements or direct effect remains controversial. This study aimed to explore the causal link between GLP-1RAs and myocardial infarction (MI) and quantify the contribution of metabolic improvements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Mendelian randomization (MR) was applied to assess the causal relationship between GLP-1RAs and MI, and two-step MR analysis was applied to quantify the mediating role of metabolic traits. The direct effect of GLP-1RAs on MI was evaluated by multivariate Mendelian randomization (MVMR). Genetic variants associated with GLP-1 receptor (GLP-1R) expression (proxying GLP-1RAs) were used as instrumental variables. Genome-wide association studies (GWAS) data for metabolic traits glycated hemoglobin (HbA1c), BMI, lipid profile, and blood pressure were sourced from the Million Veteran Program, serving as mediators. GWAS data for type 2 diabetes mellitus (T2DM) were obtained from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium, and data for MI were sourced from the UK Biobank\/Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease (CARDIoGRAMplusC4D), serving as outcomes. All GWAS data were restricted to European ancestry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Higher GLP-1R expression was correlated with a lower risk of T2DM (odds ratio 0.94 [95% CI 0.92, 0.97]) and MI (0.97 [0.95, 1.00]). Metabolic improvements mediated this association: HbA1c (36.67% [3.89, 69.44]), BMI (28.86% [2.62, 55.10]), triglycerides (18.52% [1.47, 35.57]), HDL-cholesterol (18.28% [1.45, 35.12]), and systolic blood pressure (11.55% [0.33, 22.76]). No direct effect of GLP-1R expression on MI was observed after adjusting for metabolic traits (\u03b2 = \u22120.003, P = 0.12).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>GLP-1RAs protect against MI primarily through metabolic improvements, with no direct effect independent of these pathways. These findings support prioritizing metabolic improvements to reduce cardiovascular risk with GLP-1RAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-1822","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T20:35:08Z","timestamp":1763584508000},"page":"171-178","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":9,"title":["Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study"],"prefix":"10.2337","volume":"49","author":[{"given":"Jingkai","family":"Tong","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Tianjin First Central Hospital 1 , Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Li","sequence":"additional","affiliation":[{"name":"Teaching Research Department, Tianjin First Central Hospital 2 , Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2750-7145","authenticated-orcid":false,"given":"Fang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin First Central Hospital 3 , Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Yue","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Tianjin First Central Hospital 4 , Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2026060411121670900_B1","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: Standards of Care in Diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2026060411121670900_B2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026060411121670900_B3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.adn4128","article-title":"The benefits of GLP-1 drugs beyond obesity","volume":"385","author":"Drucker","year":"2024","journal-title":"Science"},{"key":"2026060411121670900_B4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2026060411121670900_B5","doi-asserted-by":"crossref","first-page":"2S3","DOI":"10.1016\/S1262-3636(17)30067-8","article-title":"After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?","volume":"43","author":"Verg\u00e8s","year":"2017","journal-title":"Diabetes Metab"},{"key":"2026060411121670900_B6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2026060411121670900_B7","doi-asserted-by":"crossref","first-page":"111685","DOI":"10.1016\/j.diabres.2024.111685","article-title":"Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL","volume":"212","author":"Gooding","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2026060411121670900_B8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00395-025-01096-y","article-title":"Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion","volume":"120","author":"Chen","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"2026060411121670900_B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2023.01.049","article-title":"Semaglutide inhibits ischemia\/reperfusion-induced cardiomyocyte apoptosis through activating PKG\/PKC\u03b5\/ERK1\/2 pathway","volume":"647","author":"Zhu","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"2026060411121670900_B10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026060411121670900_B11","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2026060411121670900_B12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nature24277","article-title":"Genetic effects on gene expression across human tissues","volume":"550","author":"GTEx Consortium; Laboratory, Data Analysis &Coordinating Center (LDACC)\u2014Analysis Working Group; Statistical Methods groups\u2014Analysis Working Group; Enhancing GTEx (eGTEx) groups,","year":"2017","journal-title":"Nature"},{"key":"2026060411121670900_B13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41586-024-07019-6","article-title":"Genetic drivers of heterogeneity in type 2 diabetes pathophysiology","volume":"627","author":"Suzuki","year":"2024","journal-title":"Nature"},{"key":"2026060411121670900_B14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/eurheartj\/ehaa1040","article-title":"Genome-wide analysis identifies novel susceptibility loci for myocardial infarction","volume":"42","author":"Hartiala","year":"2021","journal-title":"Eur Heart J"},{"key":"2026060411121670900_B15","doi-asserted-by":"crossref","first-page":"eadj1182","DOI":"10.1126\/science.adj1182","article-title":"Diversity and scale: genetic architecture of 2068 traits in the VA Million Veteran Program","volume":"385","author":"Verma","year":"2024","journal-title":"Science"},{"key":"2026060411121670900_B16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12916-024-03486-w","article-title":"Do iron homeostasis biomarkers mediate the associations of liability to type 2 diabetes and glycemic traits in liver steatosis and cirrhosis: a two-step Mendelian randomization study","volume":"22","author":"Liang","year":"2024","journal-title":"BMC Med"},{"key":"2026060411121670900_B17","doi-asserted-by":"crossref","first-page":"a038984","DOI":"10.1101\/cshperspect.a038984","article-title":"Multivariable Mendelian randomization and mediation","volume":"11","author":"Sanderson","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026060411121670900_B18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/dom.14666","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: a meta-analysis and meta-regression analysis","volume":"24","author":"Yoshiji","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026060411121670900_B19","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy","volume":"66","author":"Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"2026060411121670900_B20","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.2337\/dc20-3097","article-title":"Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the Epidemiology of Diabetes Interventions and Complications (EDIC)","volume":"44","author":"Lachin","year":"2021","journal-title":"Diabetes Care"},{"key":"2026060411121670900_B21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"key":"2026060411121670900_B22","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"2026060411121670900_B23","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026060411121670900_B24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10741-024-10438-2","article-title":"Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction","volume":"30","author":"Wang","year":"2025","journal-title":"Heart Fail Rev"},{"key":"2026060411121670900_B25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026060411121670900_B26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-024-00089-1","article-title":"Dual-acting GLP-1 conjugate enhances weight loss","volume":"23","author":"Crunkhorn","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026060411121670900_B27","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"2026060411121670900_B28","doi-asserted-by":"crossref","first-page":"e3367","DOI":"10.1002\/dmrr.3367","article-title":"High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects","volume":"37","author":"Scicali","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"2026060411121670900_B29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCRESAHA.123.321563","article-title":"HDL function and atherosclerosis: reactive dicarbonyls as promising targets of therapy","volume":"132","author":"Linton","year":"2023","journal-title":"Circ Res"},{"key":"2026060411121670900_B30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: evidence and practical applications","volume":"21","author":"Ference","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026060411121670900_B31","doi-asserted-by":"crossref","first-page":"24103","DOI":"10.1038\/s41598-025-09807-0","article-title":"Efficacy and safety of GLP-1 agonists in the treatment of T2DM: a systematic review and network meta-analysis","volume":"15","author":"Ren","year":"2025","journal-title":"Sci Rep"},{"key":"2026060411121670900_B32","doi-asserted-by":"crossref","first-page":"106951","DOI":"10.1016\/j.medcli.2025.106951","article-title":"GLP-1 receptor agonists in obesity treatment: effects on cardiometabolic variables and cardiovascular disease","volume":"165","author":"Sard\u00e0","year":"2025","journal-title":"Med Clin (Barc)"},{"key":"2026060411121670900_B33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrcardio.2017.118","article-title":"Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases","volume":"15","author":"Bartoloni","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026060411121670900_B34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jama.2019.21402","article-title":"Association of isolated diastolic hypertension as defined by the 2017 ACC\/AHA blood pressure guideline with incident cardiovascular outcomes","volume":"323","author":"McEvoy","year":"2020","journal-title":"JAMA"},{"key":"2026060411121670900_B35","doi-asserted-by":"crossref","first-page":"102789","DOI":"10.1016\/j.eclinm.2024.102789","article-title":"GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review","volume":"75","author":"Jarade","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026060411121670900_B36","doi-asserted-by":"crossref","first-page":"JC52","DOI":"10.7326\/ACPJ202011170-052","article-title":"In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA1c and SBP and may reduce body weight","volume":"173","author":"Tanner","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026060411121670900_B37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-024-02203-4","article-title":"Evidence that tirzepatide protects against diabetes-related cardiac damages","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026060411121670900_B38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/cvr\/cvaa211","article-title":"Inflammation and cardiovascular diseases: lessons from seminal clinical trials","volume":"117","author":"Liberale","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026060411121670900_B39","first-page":"ehaf690","article-title":"Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial","author":"Park","year":"2025","journal-title":"Eur Heart J"},{"key":"2026060411121670900_B40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12933-022-01613-6","article-title":"Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis","volume":"21","author":"Wang","year":"2022","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/1\/171\/847898\/dc251822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/1\/171\/847898\/dc251822.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:12:26Z","timestamp":1780585946000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/1\/171\/163853\/Metabolic-Improvement-Mediates-the-Causal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-1822","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.30455684.v1","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.30455684","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}